Global Xerostomia Treatment Market Report and Forecast 2025-2034

Global Xerostomia Treatment Market Outlook

The global xerostomia treatment market is expected to grow at a CAGR of 3.5 % in the forecast period of 2025-2034.

 Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Robust Healthcare System and Awareness Programs in North America to Boost the Market Growth

North America is expected to lead the market for xerostomia treatment, followed by Europe. The major factors governing the market dominance include prominent growth in the number of xerostomia cases as well as other diseases that lead to dry-mouths, such as Sjogren's syndrome, rheumatoid arthritis, and HIV. The large number is also due to the significant geriatric population in these areas. Awareness camps are frequently conducted by various organizations across the US and Canada by the Sjogren's Syndrome Foundation about the disease. Ease of access and availability of healthcare facilities, and robust medical infrastructure with conducive compensation scenarios are some of the important factors, which are helping the market grow in North America. As the Asia-Pacific region is expected to grow at a fast rate during the forecast period, and as healthcare expenditure and awareness about various health conditions improve, the market for xerostomia therapies is expected to grow in these regions. Ailments such as Parkinson’s disease, cancer, diabetes mellitus, are a few of the dry mouth associated diseases. As the awareness of these diseases increases, the market for xerostomia is, in turn, expected to rise over the forecast period.

Xerostomia Treatment: Market Segmentation

Xerostomia, also known as the dry-mouth condition, is a state of lack of saliva production in the mouth. This might also be a consequence of the change in the quality of saliva produced. Normally, it arises due to many different reasons, such as side effects of medicine, dehydration, mouth bleeding, adverse effects of radiation especially due to radiation in surgery, cigarette smoking. Xerostomia is seen as a by-product of other health conditions and is not considered a disease. This condition is majorly observed in the elderly population. Chemotherapy, Sjogren’s Syndrome and HIV are also some of the dry mouth associated diseases.

 Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on product, the industry is segmented into:

• Artificial Saliva
• Salivary Stimulants
• Saliva Substitutes
• Drugs
• Salivary Pens
• Others

By type, the industry is bifurcated into:

• OTC
• Prescription

On the basis of distribution channels, the industry is segregated into:

• Hospital Pharmacies
• Retail Pharmacies
• Online
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Rising Cases of Lifestyle Diseases to Boost the Market for Xerostomia Treatment

The increasing consumption and dependence on medication is the major driver for the rise of xerostomia treatment industry. A growing number of cases of Sjogren's syndrome as well as diagnosis of it is also a major driver of this market. Moreover, as the geriatric population is increasing across the globe, coupled with increasing cases of chronic and lifestyle related diseases, the market is expected to enhance during the forecast period. There has been a rising awareness towards the diagnosis of xerostomia in recent years is aiding the market growth. This is expected to boost the market growth in the forecast period as well. Further, the increase in the cases of diseases such as cancer, HIV, and Sjogren’s syndrome drives the demand for radiation and chemotherapy. Xerostomia is a side-effect of these treatments. However, lack of health awareness towards xerostomia in developing countries is expected to decelerate the growth of this market.

Key Industry Players in the Global Xerostomia Treatment Market

The report gives a detailed analysis of the following key players in the global xerostomia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• 3M Co.
• GlaxoSmithKline plc
• Saliwell Ltd
• Sun Pharmaceutical Industries Ltd
• Cumberland Pharmaceuticals Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report